Drug Monograph
Oxybutynin (Ditropan / Ditropan XL)
oxybutynin chloride
Pharmacokinetic Profile
Half-Life
IR: 2–3 h; ER: ~13 h
Metabolism
CYP3A4 (liver & gut wall)
Protein Binding
>99%
Bioavailability
~6% oral (range 1.6–10.9%)
Volume of Distribution
193 L (IV data)
Clinical Information
Drug Class
Antimuscarinic (anticholinergic)
Available Doses
IR: 5 mg tab; ER: 5, 10, 15 mg tab; Patch: 3.9 mg/day; Gel: 10%
Route
Oral, Transdermal
Renal Adjustment
Not studied
Hepatic Adjustment
Not studied
Pregnancy
Insufficient data; use only if benefit outweighs risk
Lactation
Unknown if excreted in milk; use caution
Schedule / Legal Status
Rx; Oxytrol patch OTC for women ≥18
Generic Available
Yes (all formulations)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Overactive bladder — urge incontinence, urgency, frequency | Adults | Monotherapy (all formulations) | FDA Approved |
| Detrusor overactivity — neurogenic bladder (e.g., spina bifida) | Paediatric ≥5 y (IR); ≥6 y (ER) | Monotherapy | FDA Approved |
Oxybutynin is one of the oldest and most widely prescribed antimuscarinics for overactive bladder (OAB), with an initial US approval in 1975. It is available in four FDA-approved formulations: immediate-release tablets/syrup, extended-release tablets (OROS technology), a transdermal patch, and a topical gel. The AUA/SUFU guideline (2024) recommends antimuscarinic medications as pharmacotherapy for OAB, with a preference for extended-release over immediate-release formulations due to lower dry mouth rates. Transdermal oxybutynin is specifically offered as an option for patients who cannot tolerate oral anticholinergics.
Off-Label Uses
Hyperhidrosis (excessive sweating): Oxybutynin 5–10 mg/day has been used off-label for generalized and focal hyperhidrosis, supported by several small RCTs and case series. Evidence quality: Moderate
Bladder spasms from indwelling catheters or ureteral stents: Commonly used in clinical practice to manage catheter-related bladder irritation. Evidence quality: Low
Paediatric OAB (<5 years, off-label): Used at 0.2 mg/kg orally 2–4 times daily, max 15 mg/day, in children aged 1–5 years. Evidence quality: Low
Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| OAB — adult, immediate-release oral | 5 mg BID–TID | 5 mg BID–TID | 20 mg/day (5 mg QID) | Higher dry mouth rate than ER; consider ER as first-line oral Also available as 5 mg/5 mL syrup |
| OAB — adult, extended-release oral | 5–10 mg once daily | 10–15 mg once daily | 30 mg/day | Titrate by 5 mg weekly; swallow whole, do not crush/chew Tablet shell excreted in faeces (normal finding) |
| OAB — adult, transdermal patch (Oxytrol) | 3.9 mg/day patch | 3.9 mg/day patch | 3.9 mg/day | Apply to abdomen, hip, or buttock; change twice weekly (every 3–4 days) Rotate application sites; OTC for women ≥18 years |
| OAB — adult, topical gel (Gelnique) | 1 g (100 mg) once daily | 1 g once daily | 1 g/day | Apply to thigh, abdomen, upper arm, or shoulder; allow to dry before dressing Avoid skin-to-skin transfer to others; cover site with clothing |
| Neurogenic detrusor overactivity — paediatric ≥5 y (IR) | 5 mg BID | 5 mg BID–TID | 15 mg/day (5 mg TID) | For children over 5 years of age using IR tablets/syrup |
| Neurogenic detrusor overactivity — paediatric ≥6 y (ER) | 5 mg once daily | 5–15 mg once daily | 20 mg/day | Titrate by 5 mg weekly; child must be able to swallow tablet whole |
| Frail elderly — IR formulation | 2.5 mg BID–TID | 2.5–5 mg BID–TID | 20 mg/day | Start low; increased CNS sensitivity to anticholinergics in elderly Consider transdermal formulations or alternative agents for cognitive safety |
Clinical Pearl — Formulation Selection Matters
The AUA/SUFU guideline recommends extended-release formulations over immediate-release when both are available, primarily to reduce the incidence of dry mouth (34.9% ER vs. 72.4% IR in pivotal trials). Transdermal formulations bypass first-pass hepatic metabolism, producing less N-desethyloxybutynin (the metabolite most responsible for dry mouth and CNS effects) and are a valuable option for patients who experience intolerable anticholinergic side effects with oral therapy.
Pharmacology
Mechanism of Action
Oxybutynin is a racemic mixture of R- and S-enantiomers that acts as a competitive antagonist of acetylcholine at postganglionic muscarinic receptors. The antimuscarinic activity resides predominantly in the R-isomer. In addition to its antimuscarinic effects, oxybutynin exerts a direct antispasmodic effect on detrusor smooth muscle, independent of cholinergic blockade. It does not block nicotinic receptors at the neuromuscular junction or autonomic ganglia. In patients with involuntary detrusor contractions, oxybutynin increases bladder capacity, diminishes the frequency of uninhibited contractions, and delays the initial desire to void, resulting in reduced urgency, fewer incontinence episodes, and decreased urinary frequency. The active metabolite N-desethyloxybutynin has similar pharmacological activity on bladder muscle but is the principal driver of anticholinergic side effects, particularly dry mouth, due to its higher circulating concentrations with oral formulations.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | IR: rapid, Tmax ~1 h, bioavailability ~6% (extensive first-pass); ER: gradual, Tmax ~12–13 h; Transdermal: Tmax 24–48 h, steady state at 2nd application | Very low oral bioavailability reflects extensive first-pass metabolism; transdermal bypasses this, producing lower N-desethyloxybutynin levels |
| Distribution | Vd 193 L (IV); protein binding >99% (both enantiomers); crosses blood–brain barrier | CNS penetration explains cognitive side effects, especially in elderly; large Vd indicates extensive tissue distribution |
| Metabolism | Hepatic and gut wall via CYP3A4; major metabolites: N-desethyloxybutynin (active) and phenylcyclohexylglycolic acid (inactive) | N-desethyloxybutynin is 73–92% of parent drug levels with ER; transdermal produces a lower metabolite-to-parent ratio, reducing side effects |
| Elimination | IR: t½ ~2–3 h; ER: t½ ~13 h; <0.1% excreted unchanged in urine | Essentially no renal excretion of parent drug; dose adjustment for renal impairment not formally addressed but unlikely to be required |
Side Effects
≥10%
Very Common
| Adverse Effect | Incidence (ER) | Incidence (IR) | Clinical Note |
|---|---|---|---|
| Dry mouth | 34.9% | 72.4% | Most common reason for discontinuation; markedly lower with ER and transdermal formulations; sugarless gum, saliva substitutes can help |
| Constipation | 8.7% | 15.1% | Exceeds 10% with IR; anticholinergic effect on GI motility; increase fibre, fluids; consider osmotic laxative if needed |
| Dizziness | 5.0% | 16.6% | Exceeds 10% with IR; substantially reduced with ER formulation; falls risk in elderly |
| Somnolence | 5.6% | 14.1% | Exceeds 10% with IR; warn patients about driving and operating machinery |
| Nausea | 4.5% | 11.6% | Exceeds 10% with IR; tends to improve after the first week of therapy |
1–10%
Common (ER Formulation)
| Adverse Effect | Incidence (ER) | Clinical Note |
|---|---|---|
| Diarrhoea | 7.9% | Paradoxical GI effect; monitor hydration |
| Headache | 7.5% | Usually mild and self-limiting |
| Dyspepsia | 4.5% | Take with food if needed |
| Blurred vision | 4.3% (9.6% IR) | Anticholinergic effect on ciliary muscle; more pronounced with IR |
| Dry eye | 3.1% | Consider artificial tears; caution in contact lens wearers |
| Insomnia | 3.0% | Consider morning dosing |
| Fatigue | 2.6% | May overlap with somnolence |
| Residual urine volume increase | 2.3% | Monitor in patients at risk for retention |
| Urinary hesitation | 1.9% (8.5% IR) | Dose-reduce or discontinue if symptomatic retention develops |
| Dry skin | 1.8% | Anticholinergic effect on sweat glands; heat prostration risk in hot environments |
| Nasal dryness | 1.7% | Saline nasal spray may provide relief |
| Urinary retention | 1.2% (3.0% IR) | Contraindicated in patients with pre-existing urinary retention |
Serious
Serious (Regardless of Frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Angioedema (face, lips, tongue, larynx) | Rare (postmarketing) | May occur after first dose | Discontinue immediately; ensure patent airway; emergency treatment; do not rechallenge |
| Anaphylaxis | Rare (postmarketing) | Any time | Discontinue; emergency treatment including epinephrine; permanent discontinuation |
| CNS anticholinergic effects (hallucinations, agitation, confusion) | Rare (postmarketing) | First months, especially after dose increases | Dose reduction or discontinuation; evaluate for delirium; higher risk in elderly and dementia patients |
| Cognitive impairment (memory, attention) | Not quantified; class effect | Insidious; may develop over weeks to months | Use lowest effective dose; consider non-anticholinergic alternatives in elderly; anticholinergic burden assessment |
| QT interval prolongation | Rare (postmarketing) | Variable | ECG if symptomatic; avoid with other QT-prolonging drugs; correct electrolytes |
| Heat prostration (fever, heat stroke) | Rare | Hot environments | Counsel patients to avoid excessive heat; reduced sweating is a class effect; hydrate adequately |
| Convulsions | Very rare (postmarketing) | Variable | Discontinue; neurological evaluation; may relate to anticholinergic toxicity |
Discontinuation
Discontinuation Rates
Extended-Release (Ditropan XL)
4.4%
Top reason: Dry mouth (0.7%)
Immediate-Release
0% (in controlled trials)
Note: 0% rate may reflect smaller sample size and trial design; real-world discontinuation due to dry mouth is substantially higher with IR
| Reason for Discontinuation | Incidence (ER) | Context |
|---|---|---|
| Dry mouth | 0.7% | Most common reason; real-world rates higher than clinical trial estimates |
| CNS effects (somnolence, dizziness) | <1% | More common in elderly patients |
| GI effects (constipation, nausea) | <1% | Usually manageable with dose adjustment |
Management — Dry Mouth
Dry mouth is the most prevalent barrier to oxybutynin adherence and is driven primarily by the active metabolite N-desethyloxybutynin. Practical strategies include switching from IR to ER formulation (reduces incidence from ~72% to ~35%), switching to transdermal delivery, using sugarless gum or candy, maintaining adequate hydration, and using saliva substitutes (e.g., carboxymethylcellulose-based products). If dry mouth remains intolerable, switching to an alternative antimuscarinic with a more favourable side-effect profile (e.g., solifenacin, fesoterodine) or to mirabegron (beta-3 agonist) should be considered.
Drug Interactions
Oxybutynin is metabolised primarily by CYP3A4. It does not appear to be a significant inhibitor or inducer of CYP enzymes at clinical doses. The principal interaction concern is additive anticholinergic toxicity when combined with other anticholinergic agents, and increased oxybutynin exposure with potent CYP3A4 inhibitors.
MajorOther anticholinergic drugs (class interaction)
MechanismAdditive muscarinic receptor blockade
EffectIncreased frequency and severity of dry mouth, constipation, urinary retention, CNS effects, heat prostration
ManagementPerform anticholinergic burden assessment (e.g., ACB scale); minimise concurrent anticholinergic prescribing, especially in elderly
FDA PIMajorCholinesterase inhibitors (donepezil, rivastigmine, galantamine)
MechanismPharmacological antagonism — anticholinergic effect opposes cholinesterase inhibitor benefit
EffectReduced efficacy of dementia treatment; worsened cognition
ManagementAvoid combination if possible; use mirabegron or non-pharmacological OAB therapy; FDA PI warns to use with caution in dementia patients
FDA PIModerateKetoconazole & other potent CYP3A4 inhibitors
MechanismCYP3A4 inhibition reduces oxybutynin metabolism
Effect~2-fold increase in oxybutynin plasma concentrations (ER); ~3–4-fold increase with IR
ManagementUse caution with itraconazole, clarithromycin, erythromycin; monitor for increased anticholinergic effects
FDA PIModerateProkinetic agents (metoclopramide, domperidone)
MechanismPharmacological antagonism — oxybutynin slows GI motility, opposing prokinetic effect
EffectReduced prokinetic efficacy
ManagementAvoid combination where possible; if both needed, assess GI symptom control
FDA PIModerateCNS depressants (alcohol, benzodiazepines, opioids)
MechanismAdditive central nervous system depression
EffectIncreased drowsiness, sedation, impaired cognition
ManagementWarn patients about additive drowsiness; alcohol may enhance sedation; avoid concurrent opioids if possible
FDA PIModerateDrugs that can exacerbate oesophagitis (bisphosphonates, potassium tablets)
MechanismOxybutynin reduces GI motility, increasing oesophageal transit time
EffectIncreased risk of oesophageal irritation/ulceration
ManagementEnsure adequate upright posture after taking bisphosphonates; consider alternative OAB therapy in patients with active GERD
FDA PIMonitoring
- Post-Void ResidualBaseline (if at risk), repeat if symptoms arise
Trigger-basedMeasure in patients with bladder outflow obstruction risk, BPH, or symptoms of voiding difficulty. Urinary retention is a contraindication. - Anticholinergic BurdenAt initiation, then at each review
RoutineAssess cumulative anticholinergic load using the Anticholinergic Cognitive Burden (ACB) scale. Oxybutynin has a high ACB score (3). Minimise concurrent anticholinergic prescribing. - Cognitive FunctionBaseline and periodically in elderly
RoutineScreen for cognitive decline, confusion, and memory impairment, especially in patients ≥65 years. Consider baseline cognitive testing (e.g., MMSE, MoCA). AUA/SUFU guideline acknowledges potential harm of antimuscarinics on cognition. - OAB Symptom DiaryBaseline, then 4–8 weeks
RoutineAUA/SUFU recommends assessment within 4–8 weeks of initiating pharmacotherapy for efficacy and side effects. Track voiding frequency, urgency episodes, and incontinence episodes. - Intraocular PressureIf known narrow-angle glaucoma
Trigger-basedOxybutynin is contraindicated in uncontrolled narrow-angle glaucoma. Patients with controlled glaucoma should be monitored in consultation with ophthalmology. - GI FunctionAt each follow-up
RoutineAssess constipation and GI motility, particularly in patients with autonomic neuropathy, severe constipation, or GERD. Gastric retention is a contraindication. - Application Site (Transdermal)At each patch/gel change
RoutineMonitor for local skin reactions (erythema, pruritus) at patch/gel application sites. Rotate sites with each new application to minimise dermatitis.
Contraindications & Cautions
Absolute Contraindications
- Urinary retention: Oxybutynin reduces detrusor contractility and may worsen incomplete emptying (FDA PI).
- Gastric retention and severe decreased GI motility: Anticholinergic effect slows gastric emptying and may cause dangerous GI obstruction (FDA PI).
- Uncontrolled narrow-angle glaucoma: Anticholinergic mydriasis may precipitate acute angle closure (FDA PI).
- Known hypersensitivity: History of angioedema, anaphylaxis, or other serious hypersensitivity to oxybutynin or any component (FDA PI).
Relative Contraindications (Specialist Input Recommended)
- Pre-existing dementia treated with cholinesterase inhibitors: Pharmacological antagonism worsens cognition and negates dementia treatment benefit. Consider mirabegron or non-pharmacological alternatives.
- Significant bladder outflow obstruction (e.g., untreated BPH): Risk of precipitating acute urinary retention. Measure post-void residual before initiating.
- Severe hepatic impairment: Not formally studied; extensive hepatic metabolism suggests increased exposure is possible.
Use with Caution
- Elderly patients (≥65 years): Increased sensitivity to anticholinergic CNS effects; higher risk of falls, cognitive impairment, and delirium. The Beers Criteria lists oxybutynin as potentially inappropriate in older adults. Prefer non-oral formulations or mirabegron/vibegron.
- Parkinson’s disease: Anticholinergic agents may worsen motor and cognitive symptoms (FDA PI).
- Myasthenia gravis: May aggravate symptoms due to muscarinic blockade (FDA PI).
- Autonomic neuropathy: Risk of worsened GI dysmotility (FDA PI).
- GERD / oesophageal disorders: Reduced GI motility may worsen reflux or increase risk of oesophageal injury from concurrent medications (FDA PI).
- Hot environments: Reduced sweating may lead to heat prostration; patients should maintain hydration and avoid excessive heat (FDA PI).
- GI narrowing (ER formulation only): Non-deformable tablet shell may cause obstruction in patients with pre-existing strictures (FDA PI).
FDA Safety Advisory
Angioedema Risk
Angioedema of the face, lips, tongue, and larynx has been reported with oxybutynin, including cases occurring after the first dose. Upper airway angioedema may be life-threatening. Patients should be advised to seek emergency medical attention immediately if they experience tongue swelling, throat tightness, or difficulty breathing. Oxybutynin should be permanently discontinued if angioedema occurs (FDA PI).
Patient Counselling
Purpose of Therapy
Oxybutynin helps control the symptoms of an overactive bladder by relaxing the bladder muscle. It reduces the urgency and frequency of urination and helps prevent accidental urine leakage. The medication works best when taken regularly and may take a few weeks to achieve its full effect.
How to Take
For extended-release tablets, swallow the whole tablet with liquid at the same time each day. Do not crush, chew, or break the tablet. It is normal to see an empty tablet shell in the stool. For immediate-release tablets, take two to three times daily as prescribed. For the patch, apply to clean, dry skin on the abdomen, hip, or buttock and change every 3 to 4 days. For the gel, apply once daily to the thigh, abdomen, upper arm, or shoulder.
Dry Mouth
Tell patientThis is the most common side effect and usually improves with continued use. Chewing sugarless gum, sipping water frequently, and using saliva substitutes can help. Switching to a different form of oxybutynin (patch or gel) may reduce this symptom.
Call prescriberIf dry mouth is severe enough to interfere with eating, sleeping, or daily activities, or if dental problems develop.
Drowsiness & Dizziness
Tell patientOxybutynin may cause drowsiness or dizziness. Do not drive or operate machinery until you know how the medication affects you. Alcohol may worsen drowsiness.
Call prescriberIf drowsiness is severe, persistent, or accompanied by confusion, hallucinations, or unusual behaviour.
Heat Sensitivity
Tell patientThis medication reduces sweating, which makes you more vulnerable to overheating. Avoid strenuous activity in hot weather, stay hydrated, and seek shade or air conditioning when temperatures are high.
Call prescriberIf you develop fever, feel faint, or experience confusion during hot weather — these may be signs of heat prostration.
Constipation
Tell patientIncrease dietary fibre, drink adequate fluids, and stay physically active. An osmotic laxative (e.g., polyethylene glycol) may be used if needed.
Call prescriberIf you have severe constipation, abdominal pain, bloating, or have not had a bowel movement in several days.
Blurred Vision
Tell patientSome blurring of vision may occur, especially with higher doses or the immediate-release form. Use caution when driving or performing tasks that require clear vision.
Call prescriberIf vision changes are persistent, worsening, or you experience eye pain (could indicate angle-closure glaucoma).
Transdermal Application (Patch/Gel)
Tell patientApply the patch or gel to clean, dry skin. Rotate application sites to prevent skin irritation. For the gel, cover the treated area with clothing to prevent transfer to others. Do not swim, bathe, or shower until the area is dry. Fold used patches in half before discarding.
Call prescriberIf persistent skin irritation, rash, or blistering develops at the application site.
Allergic Reactions
Tell patientRarely, oxybutynin can cause a serious allergic reaction with swelling of the face, lips, tongue, or throat. This can occur even after the first dose.
Call prescriberSeek emergency medical attention immediately if you experience swelling of the face or throat, difficulty breathing, or skin rash with hives.
Sources
Regulatory (PI / SmPC)
- DITROPAN XL (oxybutynin chloride) Extended Release Tablets — Full Prescribing Information. Janssen Pharmaceuticals; Revised 2021. FDA LabelPrimary source for ER dosing, adverse reaction incidence rates (Table 1), pharmacokinetic parameters, and contraindications.
- DITROPAN (oxybutynin chloride) Tablets — Full Prescribing Information. Ortho-McNeil; Revised 2009. FDA LabelSource for IR formulation dosing, paediatric dosing (≥5 years), and IR-specific adverse reaction rates.
- OXYTROL (oxybutynin transdermal system) — Full Prescribing Information. Revised 2024. FDA LabelSource for transdermal pharmacokinetics, application site data, and N-desethyloxybutynin-to-oxybutynin ratios with transdermal delivery.
Key Clinical Trials
- Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78(6):687-695. doi:10.4065/78.6.687Head-to-head comparison of oxybutynin ER vs. tolterodine ER showing comparable efficacy with different side-effect profiles.
- Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62(2):237-242. doi:10.1016/S0090-4295(03)00355-7Pivotal trial demonstrating transdermal oxybutynin efficacy with reduced dry mouth vs. oral tolterodine.
Guidelines
- Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol. 2024. doi:10.1097/JU.0000000000003985Current AUA/SUFU guideline recommending antimuscarinics or beta-3 agonists for OAB pharmacotherapy; highlights cognitive risk of antimuscarinics.
- Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202(3):558-563. doi:10.1097/JU.0000000000000309Previous guideline amendment establishing preference for ER over IR formulations and transdermal options.
- EAU Guidelines on Non-neurogenic Female LUTS. European Association of Urology; 2024. EAU GuidelinesEuropean perspective on antimuscarinic use in OAB, including safety considerations for elderly patients.
Mechanistic / Basic Science
- Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging. 1995;6(3):243-262. doi:10.2165/00002512-199506030-00007Foundational pharmacology review covering the dual antispasmodic and antimuscarinic mechanism of oxybutynin.
- Chapple CR, Yamanishi T, Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology. 2002;60(5 Suppl 1):82-88. doi:10.1016/S0090-4295(02)01803-4Review of muscarinic receptor pharmacology underlying antimuscarinic OAB therapy and subtype selectivity.
Pharmacokinetics / Special Populations
- Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol. 1999;39(3):289-296. doi:10.1177/00912709922007831Key PK study comparing ER vs. IR oxybutynin, demonstrating reduced N-desethyloxybutynin exposure with ER formulation.
- Davila GW, Daugherty CA, Sanders SW; Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol. 2001;166(1):140-145. doi:10.1016/S0022-5347(05)66093-8Demonstrated that transdermal delivery reduces dry mouth incidence compared with oral IR oxybutynin by bypassing first-pass metabolism.